The Dengue Vaccine Initiative said on Monday that it received almost $1.4 million from the German Federal Ministry of Education and Research to assist in the research and development of new dengue vaccines.
DVI will work in collaboration with the Instituto Butantan in São Paulo, Brazil, and Vabiotech in Hanoi, Vietnam.
Dengue infects humans through mosquitoes, and is prevalent in more than 120 countries. Reported cases of the infection have increased during the past 50 years, and it is a major cause of hospitalization and death among children in developing countries.
"DVI is very pleased to receive support from the BMBF in our aim to encourage the development of new vaccines against dengue," Georges Thiry, the acting director for DVI, said. "Working with these manufacturers will help ensure the availability and supply of more dengue vaccines on the market, which will help increase access and affordability of dengue vaccines for the poor."
Dengue does not have a vaccine, but several vaccine candidates are under development and in clinical phases.
"With the 1 million EUR grant to DVI, Germany is expanding its support for research for neglected and poverty-related diseases", Helge Braun, the state secretary at the German Federal Ministry of Education and Research, said. "At the same time, our support for vaccine development is reinforced. Effective vaccines and immunization strategies are vital to fight threatening infectious diseases sustainably."
DVI works with the World Health Organization, Johns Hopkins University's International Vaccine Access Center, the Sabin Vaccine Institute and the International Vaccine Institute.